Lunsumio (mosunetuzumab-axgb) - Roche
Lunsumio: Regulatory submission in Japan for 2L follicular lymphoma in 2026 (Chugai) - Oct 27, 2026 - Q3 FY2026 Results: Regulatory submission in Japan untreated follicular lymphoma in 2029 and beyond 
Japan filing • Follicular Lymphoma • Hematological Malignancies • Oncology
https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_77.pdf&src=[%0],[%1]&rep=137,77
 
Oct 27, 2026
 
 
f91a5c8b-9594-4211-a1fa-ccb28ec2cd3e.png